Merck KGaA ADR
USUSDMerck KGaA ADR (LSE:0QAH) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 6. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
- Merck KGaA — MRK · XETRA DE Registratienummer onbekend
Over het bedrijf
- Website
- merck.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- RAHWAY, Germany
- CEO
- Kai Beckmann
- Werknemers
- 62 136
- Uitstaande aandelen
- 2.47 mld. per 2026-07-31
- Free float
- 644.35 mln.
- Marktkapitalisatie
- 67.93 mld. USD
- Insiders
- 0%
- Institutionele beleggers
- 0.02%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- XSNP
- ISIN
- US58933Y1055
- LEI
- 4YV9Y5M8S0BRK1RP0397
- Uitkeringsratio
- 262%
- FCF
- 16.1 mld. USD52%
- Schuld
- 51.1 mld. USD2.8 jr FCF
- Dividendreeks
- 56+ jr
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Beurzen en tickers
| Beurs | Ticker | Valuta | Prijs | Type |
|---|---|---|---|---|
| US USA Stocks | MRK secundair | USD | 142.38 -0.29% | gewone aandelen |
| LSE London Stock Exchange | 0QAH IOB | USD | 148.65 -0.12% | gewone aandelen |
| MI Borsa Italiana (Milan) | 1MRKX primair | EUR | 129.56 +3.96% | gewone aandelen |
| MX Mexican Stock Exchange | MRK secundair | MXN | 2 561 +0.91% | gewone aandelen |
| VI Vienna Stock Exchange | MRK secundair | EUR | 124.84 -2.79% | gewone aandelen |
| XETRA Xetra | 6MK secundair | EUR | 129.78 +0.09% | gewone aandelen |
Dividenden
Merck KGaA ADR (0QAH) betaalt elk kwartaal dividend uit. In de afgelopen 12 maanden werd 3.4 USD per aandeel betaald (betalingen: 4). Dat is ongeveer 2.29% van de huidige aandelenkoers. Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 15.12.2026. Ononderbroken dividendgeschiedenis: 56 jaar.
| Ex-datum | Uitbetaling | Bedrag | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-09-15 | 2026-10-07 | 0.8500 USD | 0.6/2.3 % | per kwartaal | LSE:0QAH |
| 2026-06-15 | 2026-07-08 | 0.8500 USD | 0.6/2.3 % | per kwartaal | LSE:0QAH |
| 2026-03-16 | 2026-04-07 | 0.8500 USD | 0.6/2.2 % | per kwartaal | LSE:0QAH |
| 2025-12-15 | 2026-01-08 | 0.8500 USD | 0.6/2.2 % | per kwartaal | LSE:0QAH |
| 2025-09-15 | 2025-10-07 | 0.8100 USD | 0.5/2.2 % | per kwartaal | LSE:0QAH |
| 2025-06-16 | 2025-07-08 | 0.8100 USD | 0.5/2.2 % | per kwartaal | LSE:0QAH |
| 2025-03-17 | 2025-04-07 | 0.8100 USD | 0.5/2.1 % | per kwartaal | LSE:0QAH |
| 2024-12-16 | — | 0.8100 USD | 0.5/2.1 % | per kwartaal | LSE:0QAH |
| 2024-09-16 | — | 0.7700 USD | 0.5/2.1 % | per kwartaal | LSE:0QAH |
| 2024-06-17 | — | 0.7700 USD | 0.5/2.0 % | per kwartaal | LSE:0QAH |
| 2024-03-14 | — | 0.7700 USD | 0.5/2.0 % | per kwartaal | LSE:0QAH |
| 2023-12-14 | — | 0.7700 USD | 0.5/2.0 % | per kwartaal | LSE:0QAH |
| 2023-09-14 | — | 0.7300 USD | 0.5/2.0 % | per kwartaal | LSE:0QAH |
| 2023-06-14 | — | 0.7300 USD | 0.5/1.9 % | per kwartaal | LSE:0QAH |
| 2023-03-14 | — | 0.7300 USD | 0.5/1.9 % | per kwartaal | LSE:0QAH |
| 2022-12-14 | — | 0.7300 USD | 0.5/1.9 % | per kwartaal | LSE:0QAH |
| 2022-09-14 | — | 0.6900 USD | 0.5/1.9 % | per kwartaal | LSE:0QAH |
| 2022-06-14 | — | 0.6900 USD | 0.5/1.4 % | per kwartaal | LSE:0QAH |
| 2022-03-14 | — | 0.6900 USD | 0.5/0.9 % | per kwartaal | LSE:0QAH |
| 2021-12-14 | — | 0.6900 USD | 0.5/0.5 % | per kwartaal | LSE:0QAH |
Nieuws deze week
Nog geen nieuws van de website van het bedrijf.
Grootste aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| BlackRock | 9.2% | 227 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.54% | 161.32 mln. | 2026-06-30 |
| State Street Corporation | 4.88% | 120.41 mln. | 2026-06-30 |
| Wellington Management Gr… | 3.5% | 86.25 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 78.41 mln. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 67.74 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 64 mln. | 2026-06-30 |
| Geode Capital Management… | 2.46% | 60.74 mln. | 2026-06-30 |
| Charles Schwab Investmen… | 2.2% | 54.37 mln. | 2026-06-30 |
| Morgan Stanley | 1.97% | 48.64 mln. | 2026-06-30 |
| FMR, LLC | 1.84% | 45.44 mln. | 2026-06-30 |
| JPMORGAN CHASE & CO | 1.78% | 43.89 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 32.89 mln. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 31.94 mln. | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.25% | 30.86 mln. | 2026-05-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 30.22 mln. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 23.51 mln. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 17.75 mln. | 2026-08-31 |
| VANGUARD SPECIALIZED FUN… | 0.65% | 15.95 mln. | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 13.97 mln. | 2026-07-31 |
| DAVIS ROBERT M (Chief Ex… | ≈0.02% | 450 351 | 2026-04-29 |
| CHATTOPADHYAY SANAT (Off… | ≈0.01% | 200 675 | 2026-04-29 |
| DELUCA RICHARD ROBERT JR… | ≈0% | 110 167 | 2026-08-12 |
| LI DEAN Y (Officer) | ≈0% | 94 431 | 2026-04-29 |
| LITCHFIELD CAROLINE (Chi… | ≈0% | 92 300 | 2026-04-29 |
| ZACHARY JENNIFER L (Gene… | ≈0% | 45 509 | 2026-08-12 |
| GUINDO CHIRFI (Officer) | ≈0% | 36 613 | 2026-08-13 |
| WILLIAMS DAVID MICHAEL (… | ≈0% | 31 716 | 2026-08-05 |
| ROMANELLI JOSEPH EDWARD… | ≈0% | 28 739 | 2026-01-26 |
| OOSTHUIZEN JOHANNES JACO… | ≈0% | 21 895 | 2026-04-29 |
| Trust for Professional M… | 0% | 24 803 | 2026-05-31 |
| Rhumbline Advisers | 0% | 10 919 | 2026-06-30 |
| SP Funds Trust-SP Funds… | 0% | 6 542 | 2026-07-31 |
| Atlas Capital Advisors I… | 0% | 2 467 | 2026-06-30 |
| Gamma Investing LLC | 0% | 2 302 | 2026-06-30 |
| Salomon & Ludwin, LLC | 0% | 356 | 2026-06-30 |
| PNC Financial Services G… | 0% | 2 | 2026-06-30 |
| The Vanguard Group | — | — | — |
